Table 2.
Uni‐ and multivariate Cox‐proportional hazards regression analysis to explore factors associated with development of thiopurine‐induced leucopenia in the first five months of thiopurine treatment in patients without a TPMT variant
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Hazard ratio (95% CIs) | P‐value | Hazard ratio (95% CIs) | P‐value | |
| Drug type, MP vs AZA | 2.45 (1.35‐4.48) | .003 | 2.61 (1.39‐4.88) | .003 |
| Week 0 WBC count, 109/L | 0.78 (0.70‐0.88) | <.001 | 0.80 (0.71‐0.89) | <.001 |
| Concomitant biologic drugs | 1.67 (0.80‐3.49) | .17 | ||
| Thiopurine dosage (mg/kg) | 5.59 (0.68‐46.1) | .11 | ||
| Active smoking | 0.37 (0.13‐1.03) | .06 | ||
AZA dose in mg/kg was divided by 2.08 to compare with MP dosage.
AZA, azathioprine; MP, mercaptopurine; WBC, white blood cell.